

**RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE REQUESTED  
EXAMINING GROUP 1625  
PATENT**

Attorney Docket No. 07541.0009

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

**Toshisada YANO et al.**

Application No.: 10/573,386

§ 371 Date: November 13, 2006

For: PIPERIDINE DERIVATIVE  
HAVING NMDA RECEPTOR  
ANTAGONISTIC ACTIVITY

)  
)  
) Group Art Unit: 1625  
)  
) Examiner: CHANG, Celia C.  
)  
) Confirmation No.: 9341  
)

**VIA EFS-WEB**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**AMENDMENT AFTER FINAL**

In reply to the Final Office Action mailed January 20, 2010, please amend the  
above-identified application as follows:

**Amendments to the Claims** are reflected in the listing of claims beginning on  
page 2 of this paper.


**Arguments/Remarks** follow the amendment section of this paper.

/CC/  
OK enter 4/22/10

**AMENDMENTS TO THE CLAIMS:**

Without prejudice or disclaimer, this listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously Presented) A compound of the formula (I):



wherein X is OH or lower alkylsulfonyloxy;

Ar is optionally substituted aryl or optionally substituted heteroaryl;

n is an integer of 1 to 4;

m is an integer of 0 to 1;

R<sup>1</sup> is hydrogen;

R<sup>2</sup> is OH or

R<sup>1</sup> and R<sup>2</sup> taken together may form a single bond;

excluding that

1) n is 2; m is 0; R<sup>1</sup> and R<sup>2</sup> taken together may form a single bond; and Ar is optionally substituted phenyl and

2) n is 3; m is 0; R<sup>1</sup> and R<sup>2</sup> taken together may form a single bond; and Ar is phenyl,

or a pharmaceutically acceptable salt or a hydrate thereof.

2. (Previously Presented) A compound according to Claim 1 wherein n is 3 or 4, or a pharmaceutically acceptable salt, or a hydrate thereof.
3. (Previously Presented) A compound according to Claim 1 wherein m is 1, or a pharmaceutically acceptable salt or a hydrate thereof.
4. (Previously Presented) A compound according to Claim 1 wherein n is 3; m is 1; and Ar is optionally substituted phenyl, or a pharmaceutically acceptable salt or a hydrate thereof.
5. (Previously Presented) A compound according to Claim 1 wherein n is 3; m is 1; R<sup>1</sup> is hydrogen; R<sup>2</sup> is OH; and Ar is optionally substituted phenyl, or a pharmaceutically acceptable salt or a hydrate thereof.
6. (Previously Presented) A compound according to Claim 1 wherein n is 3; m is 1; R<sup>1</sup> and R<sup>2</sup> taken together may form a single bond; and Ar is optionally substituted phenyl, or a pharmaceutically acceptable salt, or a hydrate thereof.
7. (Previously Presented) A compound according to Claim 1 wherein n is 3; m is 0; R<sup>1</sup> and R<sup>2</sup> taken together may form a single bond; and Ar is substituted phenyl, or a pharmaceutically acceptable salt, or a hydrate thereof.
8. (Previously Presented) A compound according to Claim 1 wherein Ar is optionally substituted heteroaryl, or a pharmaceutically acceptable salt or a hydrate thereof.
9. (Previously Presented) A compound according to Claim 1 wherein n is 3; m is 0; R<sup>1</sup> and R<sup>2</sup> taken together may form a single bond; and Ar is optionally substituted heteroaryl, or a pharmaceutically acceptable salt or a hydrate thereof.

10. (Previously Presented) A pharmaceutical composition comprising a compound according to Claim 1 and at least one pharmaceutically acceptable carrier.

11. (Previously Presented) The pharmaceutical composition according to Claim 10 having NMDA receptor antagonistic activity.

12. (Previously Presented) The pharmaceutical composition according to Claim 11 having NR1/NR2B receptor antagonistic activity.

13. (Currently Amended) A pharmaceutical composition comprising a compound according to Claim 1 which is an analgesic or a medicament for treating migraine, stroke, head injury, Alzheimer's disease, Parkinson's disease, or tinnitus.

14. (Previously Presented) A pharmaceutical composition comprising a compound according to Claim 1 which is an analgesic.

15. (Currently Amended) A method for alleviating pain or treating migraine, stroke, head injury, Alzheimer's disease, Parkinson's disease, or tinnitus comprising administering a compound according to Claim 1.

16. (Previously Presented) A method for alleviating pain comprising administering a compound according to Claim 1.

17. (Currently Amended) A method for manufacturing an analgesic or a medicament for treating migraine, stroke, head injury, Alzheimer's disease, Parkinson's disease, or tinnitus;

the method comprises using a compound according to claim 1 to manufacture the analgesic or medicament.

18. (Previously Presented) A method for manufacturing an analgesic;

the method comprising using a compound according to claim 1 to manufacture the analgesic.